Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.81 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.67 |
| ▸ | STAT3 | P40763 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | IDH1 | O75874 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.59 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.59 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11003408 | 0.90 | EPHX2 (1.00) | EPHX2MEN1KMT2AMAPTCA12 | |
| SCHEMBL28729179 | 0.90 | EPHX2 (1.00) | EPHX2MEN1KMT2AMAPTCA12 | |
| SCHEMBL8172368 | 0.88 | CA12 (0.64) | EPHX2CNR1GRIK1MEN1KMT2A | |
| SCHEMBL9688005 | 0.87 | EPHX2 (0.62) | EPHX2CNR1GRIK1P2RX1P2RX4 | |
| SCHEMBL28910371 | 0.86 | TRPV1 (0.71) | KMT2AP2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL4004073 | 0.85 | IDH1 (0.69) | EPHX2MEN1KMT2AIDH1MAPT | |
| SCHEMBL11048619 | 0.84 | MEN1 (0.76) | EPHX2CNR1GRIK1MEN1KMT2A | |
| SCHEMBL4741253 | 0.84 | MEN1 (0.76) | EPHX2CNR1GRIK1MEN1KMT2A | |
| SCHEMBL161516 | 0.84 | BAZ1A (0.71) | EPHX2GRIK1MEN1KMT2AMAPT | |
| SCHEMBL14601707 | 0.84 | KMT2A (0.77) | CNR1GRIK1MEN1KMT2AIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101516361-A | Soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS INC (US) | 2009-08-26 | — | — | CN | claimed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| CN-101516361-A | Soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS INC (US) | 2009-08-26 | — | — | CN | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | EPHX2 2759/4885CNR1 1/4885GRIK1 2383/4885 |
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | EPHX2 4066/4885CNR1 3997/4885GRIK1 4635/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | EPHX2 2759/4885CNR1 1/4885GRIK1 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.